Mammalian target of rapamycin (mTOR) inhibitor-associated non-infectious pneumonitis in patients with renal cell cancer: Predictors, management, and outcomes

BJU International

Volumn 113, Issue 3, 2014, Pages 376-382

  Atkinson, Bradley J ^a   Cauley, Diana H ^a   Ng, Chaan ^a   Millikan, Randall E ^a   Xiao, Lianchun ^a   Corn, Paul ^a   Jonasch, Eric ^a   Tannir, Nizar M ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

everolimus; pneumonitis; renal cell carcinoma (RCC); temsirolimus

Indexed keywords

ANTIBIOTIC AGENT; BRONCHODILATING AGENT; EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; TEMSIROLIMUS;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CLINICAL FEATURE; CORRELATION ANALYSIS; CORTICOSTEROID THERAPY; COUGHING; DEMOGRAPHY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; DRUG WITHDRAWAL; DYSPNEA; FEMALE; FEVER; FISHER EXACT TEST; HEMOPTYSIS; HUMAN; HUMAN TISSUE; INCIDENCE; KIDNEY METASTASIS; LOG RANK TEST; LOGISTIC REGRESSION ANALYSIS; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MORBIDITY; NON INFECTIOUS PNEUMONITIS; OVERALL SURVIVAL; OXYGEN THERAPY; PATIENT CARE; PATIENT MONITORING; PNEUMONIA; PREDICTIVE VALUE; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RADIOGRAPHY; RANK SUM TEST; RETROSPECTIVE STUDY; RISK FACTOR; THORAX PAIN; TREATMENT DURATION; TREATMENT OUTCOME;

EVEROLIMUS; PNEUMONITIS; RENAL CELL CARCINOMA (RCC); TEMSIROLIMUS;

ADRENAL CORTEX HORMONES; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRONCHODILATOR AGENTS; CARCINOMA, RENAL CELL; FEMALE; HOSPITALIZATION; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; OXYGEN; PNEUMONIA; RETROSPECTIVE STUDIES; SIROLIMUS; TOR SERINE-THREONINE KINASES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84896710026     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/bju.12420     Document Type: Article

References (35)

1. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007; 356: 2271-2281 (Pubitemid 46849157)
2. Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008; 372: 449-456
3. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Kidney Cancer. V1.2013. Available at: http://www.nccn.org/ professionals/physician-gls/pdf/kidney.pdf. Accessed May 2013
4. European Association of Urology. EAU Guidelines on Renal Cell Carcinoma. 2013. Available at: http://www.uroweb.org/gls/pdf/10-Renal-Cell-Carcinoma-LRV2. pdf. Accessed May 2013
5. Soefje SA, Karnad A, Brenner AJ,. Common toxicities of mammalian target of rapamycin inhibitors. Target Oncol 2011; 6: 125-129
6. Bellmunt J, Szczylik C, Feingold J, Strahs A, Berkenblit A,. Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features. Ann Oncol 2008; 19: 1387-1392
7. Maroto JP, Hudes G, Dutcher JP, et al. Drug-related pneumonitis in patients with advanced renal cell carcinoma treated with temsirolimus. J Clin Oncol 2011; 29: 1750-1756
8. Duran I, Siu LL, Oza AM, et al. Characterisation of the lung toxicity of the cell cycle inhibitor temsirolimus. Eur J Cancer 2006; 42: 1875-1880 (Pubitemid 44149096)
9. Motzer RJ, Escudier B, Oudard S, et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 2010; 116: 4256-4265
10. White DA, Camus P, Endo M, et al. Noninfectious pneumonitis after everolimus therapy for advanced renal cell carcinoma. Am J Respir Crit Care Med 2010; 182: 396-403
11. Dabydeen DA, Jagannathan JP, Ramaiya N, et al. Pneumonitis associated with mTOR inhibitors therapy in patients with metastatic renal cell carcinoma: incidence, radiographic findings and correlation with clinical outcome. Eur J Cancer 2012; 48: 1519-1524
12. National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE). Version 4.0. Available at: http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE-4. 03-2010-06-14-QuickReference-5x7.pdf. Accessed May 1, 2013
13. Dancey J,. mTOR signaling and drug development in cancer. Nat Rev Clin Oncol 2010; 7: 209-219
14. Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 2012; 366: 520-529
15. Yao JC, Shah MH, Ito T, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011; 364: 514-523
16. Albiges L, Chamming's F, Duclos B, et al. Incidence and management of mTOR inhibitor-associated pneumonitis in patients with metastatic renal cell carcinoma. Ann Oncol 2012; 23: 1943-1953
17. Morelon E, Stern M, Israel-Biet D, et al. Characteristics of sirolimus-associated interstitial pneumonitis in renal transplant patients. Transplantation 2001; 72: 787-790 (Pubitemid 32879846)
18. Pham PT, Pham PC, Danovitch GM, et al. Sirolimus-associated pulmonary toxicity. Transplantation 2004; 77: 1215-1220 (Pubitemid 38580300)
19. Dancey JE, Dobbin KK, Groshen S, et al. Guidelines for the development and incorporation of biomarker studies in early clinical trials of novel agents. Clin Cancer Res 2010; 16: 1745-1755
20. Dienstmann R, Brana I, Rodon J, Tabernero J,. Toxicity as a biomarker of efficacy of molecular targeted therapies: focus on EGFR and VEGF inhibiting anticancer drugs. Oncologist 2011; 16: 1729-1740
21. Ding K, Pater J, Whitehead M, Seymour L, Shepherd FA,. Validation of treatment induced specific adverse effect as a predictor of treatment benefit: a case study of NCIC CTG BR21. Contemp Clin Trials 2008; 29: 527-536
22. Gatzemeier U, von Pawel J, Vynnychenko I, et al. First-cycle rash and survival in patients with advanced non-small-cell lung cancer receiving cetuximab in combination with first-line chemotherapy: a subgroup analysis of data from the FLEX phase 3 study. Lancet Oncol 2011; 12: 30-37
23. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 2010; 11: 21-28
24. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351: 337-345 (Pubitemid 38944402)
25. Van Cutsem E, Peeters M, Siena S, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007; 25: 1658-1664 (Pubitemid 46797944)
26. Peeters M, Siena S, Van Cutsem E, et al. Association of progression-free survival, overall survival, and patient-reported outcomes by skin toxicity and KRAS status in patients receiving panitumumab monotherapy. Cancer 2009; 115: 1544-1554
27. Rini BI, Halabi S, Rosenberg JE, et al. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol 2010; 28: 2137-2143
28. Rixe O, Billemont B, Izzedine H,. Hypertension as a predictive factor of Sunitinib activity. Ann Oncol 2007; 18: 1117 (Pubitemid 47050505)
29. Rini BI, Cohen DP, Lu DR, et al. Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 2011; 103: 763-773
30. Grunwald V, Fishman MN, Carducci M, et al. Clinic and home blood pressure measurements are reliable for guiding therapy in patients with metastatic renal cell carcinoma receiving Axitinib as first-line therapy. Ann Oncol 2012; 23: (Suppl. 9) 268
31. Rini BI, Schiller JH, Fruehauf JP, et al. Association of diastolic blood pressure (dBP) >= 90 mmHg with overall survival (OS) in patients treated with axitinib (AG-013736). J Clin Oncol 2008; 26 (Suppl. 15): 3543
32. Wolter P, Stefan C, Decallonne B, et al. The clinical implications of sunitinib-induced hypothyroidism: a prospective evaluation. Br J Cancer 2008; 99: 448-454
33. Baldazzi V, Tassi R, Lapini A, Santomaggio C, Carini M, Mazzanti R,. The impact of sunitinib-induced hypothyroidism on progression-free survival of metastatic renal cancer patients: a prospective single-center study. Urol Oncol 2012; 30: 704-710
34. Schmidinger M, Vogl UM, Bojic M, et al. Hypothyroidism in patients with renal cell carcinoma: blessing or curse? Cancer 2011; 117: 534-544
35. Mandrekar SJ, Sargent DJ,. Clinical trial designs for predictive biomarker validation: theoretical considerations and practical challenges. J Clin Oncol 2009; 27: 4027-4034